Genedata AG Will Be Featured at Protein Engineering Summit - PEGS 2011
Published: May 09, 2011
"Biopharmaceuticals is the fastest growing market segment in the pharmaceutical industry; however, the discovery and development process for biologics molecules is extremely complex, labor intensive, and costly," said Dr. Othmar Pfannes, CEO of Genedata. "With Genedata Biologics, we provide the first integrated platform supporting the entire biologics R&D process. The system allows the collection of all relevant experimental data generated along the biologics R&D process and makes these data available to all involved laboratories and project managers. Therefore, data and material handovers from lab-to-lab are greatly facilitated, and decision making is put onto a solid foundation based on experimental data. This helps to make our customers' overall biologics discovery and development processes more efficient and ensures consistently high quality standards across different laboratories."
Genedata Biologics Saves Millions in R&D Dollars
"Genedata Biologics makes biologics discovery more efficient and can easily save millions of R&D dollars," continued Pfannes. Based on more than four years of development in close collaboration with international pharmaceutical and biotechnology customers, Genedata Biologics is an off-the-shelve software platform that allows the provisioning of focused solutions for specific parts of biologics R&D with modules that address:
- Antibody Screening for antibody selection and screening, including tools for sample management and plate logistics, integrated sequence and assay analysis, and molecule registration; to address company-specific requirements for phage-display, SLAM, or hybridoma data.
- Protein Engineering for supporting protein engineering and optimization workflows, including automated construct and plasmid design, antibody reformatting and protein engineering activities including germlining and humanization.
- Protein Production for molecular biology, cell line development, protein expression, and protein purification processes, including tools for vector design, sample management and analytics data management.
Based on a comprehensive biologics registration infrastructure, the system comes with built-in engines to ensure uniqueness of biologics molecules and materials - for both proteins and antibodies; and classical as well as next-generation format molecules. These capabilities advance high-quality standards and avoid duplicated efforts. Providing easy data access for all biologics molecules and materials, the system provides flexible tools for naming, association, searching, retrieving, analyzing, and reporting.
With an Oracle®-based database infrastructure and a web-based front-end, Genedata Biologic's open design allows seamless interfacing and integration with existing corporate IT infrastructures and laboratory instruments. The system is equipped with a default configuration that minimizes set-up and customization efforts, and lowers implementation costs. Genedata Biologics can be easily configured to support corporate-specific variants of biologics R&D workflows such as handling of proprietary libraries, workflows, or molecule formats.
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery and life science research, which spans target, lead, and biomarker discovery. Used by a majority of the world's top 50 pharmaceutical companies and leading research organizations, Genedata Phylosopher®, Genedata Screener®, Genedata Expressionist®, Genedata Analyst™, Genedata Selector™, and Genedata Biologics™ make research data accessible and understandable, enabling scientific discovery that fights disease and improves health worldwide. Founded in 1997, Genedata is privately held, with offices in Switzerland, Germany, Japan, and the US.
Marketing & Communications
Phone: +41 61 511 8459
Phone: +1 508 881 3109
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.